RNA polymerase I and III subunit DGenealiases: AC19 · RPA16 · RPA9 · RPAC2 · RPC16 · RPO1-3
Q-omics provides the consensus-scored POLR1D profile across patient tissues and cancer cell-line models. POLR1D expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, POLR1D is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, POLR1D protein abundance shows 28,201 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where POLR1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR1D survival associations across molecular data types. POLR1D RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR1D RNA expression–survival associations across cancer types. High POLR1D expression shows unfavorable associations in HNSC, CESC, ACC and ESCA, but favorable associations in KIRC and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for POLR1D RNA expression.
This table summarizes POLR1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR1D shows higher tumor expression in KIRC, COAD, LIHC, HNSC, KIRP and CHOL. The KIRC box plot shows higher POLR1D RNA expression in tumor versus normal tissue (log2 FC = +0.921, t-test p < 0.001).
This table shows molecular features associated with POLR1D in patient tissues and cancer cell lines. In patient samples, POLR1D shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
